Cara Therapeutics, Inc. (CARA)
NASDAQ: CARA · Real-Time Price · USD
0.378
-0.072 (-15.98%)
At close: Dec 27, 2024, 4:00 PM
0.387
+0.009 (2.49%)
After-hours: Dec 27, 2024, 7:43 PM EST
Cara Therapeutics Revenue
Cara Therapeutics had revenue of $2.56M in the quarter ending September 30, 2024, a decrease of -47.47%. This brings the company's revenue in the last twelve months to $8.69M, down -59.08% year-over-year. In the year 2023, Cara Therapeutics had annual revenue of $20.97M, down -49.92%.
Revenue (ttm)
$8.69M
Revenue Growth
-59.08%
P/S Ratio
2.38
Revenue / Employee
$157,927
Employees
55
Market Cap
20.74M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 20.97M | -20.90M | -49.92% |
Dec 31, 2022 | 41.87M | 18.84M | 81.81% |
Dec 31, 2021 | 23.03M | -112.05M | -82.95% |
Dec 31, 2020 | 135.08M | 115.20M | 579.28% |
Dec 31, 2019 | 19.89M | 6.42M | 47.64% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 393.90B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
CARA News
- 2 days ago - Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split - GlobeNewsWire
- 11 days ago - Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement - GlobeNewsWire
- 7 months ago - These Cara Therapeutics Analysts Are No Longer Bullish: 'We See No Obvious Future Value Drivers' - Benzinga
- 7 months ago - Cara Therapeutics discontinues study on a neurological condition as drug fails - Reuters
- 7 months ago - Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica - GlobeNewsWire
- 8 months ago - Cara Therapeutics Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 8 months ago - Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024 - GlobeNewsWire
- 9 months ago - Cara Therapeutics, Inc. (CARA) to Present at the 23rd Annual Needham Virtual Healthcare Conference - MarijuanaStocks